Editas Medicine, Inc. - Laporan Laba Rugi (TTM)

Editas Medicine, Inc.
US ˙ NasdaqGS ˙ US28106W1036

Laporan Laba Rugi (TTM)

Laporan Laba Rugi Editas Medicine, Inc. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 92 91 92 81 24 26 26 32 26 20 23 19 25 78 69 67 62 32 36 39
Change (%) -0.94 0.86 -11.33 -69.81 4.29 1.06 23.18 -19.36 -23.14 15.62 -15.25 27.41 217.44 -11.16 -3.42 -7.87 -47.68 10.90 8.55
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 131 158 165 171 166 143 104 148 161 175 173 161 160 178 189 213 220 199 177 139
Change (%) 20.35 4.66 3.48 -2.72 -14.39 -26.84 42.38 8.12 9.00 -0.92 -7.18 -0.51 10.97 6.18 12.95 3.34 -9.51 -11.14 -21.48
% of Revenue 143.32 174.13 180.71 210.89 679.59 557.89 403.88 466.83 625.90 887.57 760.57 833.02 650.52 227.40 271.78 317.85 356.53 616.60 494.05 357.38
Gross Operating Profit -40 -67 -74 -90 -142 -117 -78 -117 -135 -155 -151 -142 -135 -100 -119 -146 -158 -167 -141 -100
Change (%) 69.50 9.80 21.82 57.79 -17.61 -32.93 48.70 15.62 15.11 -3.02 -5.96 -4.31 -26.54 19.79 22.48 8.49 5.37 -15.41 -29.10
% of Revenue -43.32 -74.13 -80.71 -110.89 -579.59 -457.89 -303.88 -366.83 -525.90 -787.57 -660.57 -733.02 -550.52 -127.40 -171.78 -217.85 -256.53 -516.60 -394.05 -257.38
SG&A 69 68 71 79 75 76 74 69 69 71 74 74 73 70 66 67 70 72 66 61
Change (%) -1.64 5.44 11.15 -4.74 0.98 -2.49 -6.85 0.07 2.11 4.90 0.36 -1.68 -4.82 -5.27 1.52 4.63 2.71 -8.28 -8.10
% of Revenue 75.01 74.48 77.86 97.61 308.01 298.24 287.74 217.59 270.02 358.69 325.41 385.34 297.37 89.16 95.07 99.93 113.49 222.77 184.23 155.98
R&D 34 1
Change (%)
% of Revenue 132.79 6.30
OpEx 200 226 237 250 242 219 213 218 230 246 249 235 233 247 255 280 290 271 243 200
Change (%) 12.79 4.90 5.79 -3.36 -9.60 -2.68 2.26 5.56 6.92 1.34 -5.47 -0.88 6.01 2.96 9.99 3.65 -6.56 -10.38 -17.84
% of Revenue 218.33 248.61 258.57 308.49 987.60 856.13 824.41 684.42 895.92 1,246.26 1,092.28 1,218.36 947.89 316.56 366.85 417.78 470.02 839.37 678.28 513.35
Operating Income -108 -135 -145 -169 -217 -193 -187 -186 -204 -226 -226 -216 -209 -169 -185 -213 -229 -239 -207 -161
Change (%) 24.40 7.61 16.58 28.52 -11.16 -3.18 -0.62 9.83 10.70 0.09 -4.48 -3.41 -18.92 9.48 15.01 7.28 4.55 -13.26 -22.41
% of Revenue -118.33 -148.61 -158.57 -208.49 -887.60 -756.13 -724.41 -584.42 -795.92 -1,146.26 -992.28 -1,118.36 -847.89 -216.56 -266.85 -317.78 -370.02 -739.37 -578.28 -413.35
Interest Expense -2 -4
Change (%) 91.16
% of Revenue -6.18 -10.89
Net Income -91 -116 -135 -167 -214 -193 -186 -184 -201 -220 -219 -206 -195 -153 -166 -193 -211 -237 -251 -237
Change (%) 27.10 16.39 23.47 28.14 -9.86 -3.23 -0.97 9.02 9.60 -0.67 -6.01 -5.20 -21.46 8.43 16.44 8.85 12.59 5.96 -5.72
% of Revenue -99.62 -127.82 -147.51 -205.41 -871.91 -753.61 -721.60 -580.14 -784.29 -1,118.26 -960.66 -1,065.39 -792.70 -196.13 -239.36 -288.58 -340.96 -733.72 -701.04 -608.88

Source: Capital IQ

Other Listings
DE:8EM € 2.14
GB:0IFK
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista